Vekang Pharmaceuticals: Huangjia Ruan Gan Granule initiates Phase III clinical trial.

Vekang Pharmaceutical announced that on September 25, 2025, the company, in collaboration with Yingkerui Pharmaceuticals Co., Ltd., has initiated Phase III clinical trials for the Huanjia Ruangan Granules. The trial is led by Shuguang Hospital, affiliated with Shanghai University of Traditional Chinese Medicine, with a total of 19 clinical trial centers participating. The trial aims to evaluate the effectiveness and safety of Huanjia Ruangan Granules in treating liver fibrosis in patients with chronic hepatitis B, and plans to enroll 480 subjects. Previously, Huanjia Ruangan Granules had completed Phase II clinical trials, with results showing good clinical efficacy and safety. The company will disclose relevant information in a timely manner based on the progress of the trial.